secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001728117-22-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio reports FY2021 net loss of $234M; cash $325M; pipeline milestones set for 2022
--------------------------------------------------------------------------------

- Net loss for Q4 2021 was $56.3M ($0.74/share); FY2021 net loss $234M ($3.13/share).
- Cash, cash equivalents and marketable securities totaled $325.2M at year-end 2021; expected to fund into H2 2023.
- GB004 Phase 2 SHIFT-UC topline data (mild-to-moderate UC) expected Q2 2022; treat-through week 36 data in Q4 2022.
- Seralutinib (GB002) Phase 2 TORREY PAH study topline data expected H2 2022, subject to COVID-19 developments.
- GB5121 IND active; global Phase 1b/2 trial for primary CNS lymphoma expected to initiate in H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000018/0001728117-22-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000018/goss-20220303.htm
  HTML page:      https://secwatch.observer/filing/0001728117-22-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer